Kaho Yokoyama

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Natalizumab, a humanized monoclonal antibody against very late antigen-4 (VLA-4), inhibits the transmigration of immune cells across the bloodbrain barrier into the central nervous system (CNS). However, progressive multifocal leukoencephalopathy (PML) is caused following natalizumab treatment in patients with relapsing remitting multiple sclerosis (RRMS).(More)
  • 1